Elsewhere, BCL-XL inhibition has enhanced chemosensitivity in lung [53], colorectal [54], triple-negative breast [27] and ovarian cancer [55], as well as osteosarcoma [56], mesothelioma [57], glioblastoma [58], and solid paediatric malignancies including rhabdomyosarcoma [59]. This evidence concerns the gene BCL2L1 and ovarian carcinoma.